Cargando…

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC

Background/Aims: Lenvatinib was recently approved as a first-line oral multikinase inhibitor for unresectable hepatocellular carcinoma (HCC). In this study, we aimed to compare the efficacy and safety of lenvatinib and sorafenib for the treatment of unresectable HCC in patients with prior failure of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jaejun, Sung, Pil Soo, Yang, Hyun, Lee, Soon Kyu, Nam, Hee Chul, Yoo, Sun Hong, Lee, Hae Lim, Kim, Hee Yeon, Lee, Sung Won, Kwon, Jung Hyun, Jang, Jeong Won, Kim, Chang Wook, Nam, Soon Woo, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767204/
https://www.ncbi.nlm.nih.gov/pubmed/33371271
http://dx.doi.org/10.3390/jcm9124121
_version_ 1783628900901847040
author Lee, Jaejun
Sung, Pil Soo
Yang, Hyun
Lee, Soon Kyu
Nam, Hee Chul
Yoo, Sun Hong
Lee, Hae Lim
Kim, Hee Yeon
Lee, Sung Won
Kwon, Jung Hyun
Jang, Jeong Won
Kim, Chang Wook
Nam, Soon Woo
Bae, Si Hyun
Choi, Jong Young
Yoon, Seung Kew
author_facet Lee, Jaejun
Sung, Pil Soo
Yang, Hyun
Lee, Soon Kyu
Nam, Hee Chul
Yoo, Sun Hong
Lee, Hae Lim
Kim, Hee Yeon
Lee, Sung Won
Kwon, Jung Hyun
Jang, Jeong Won
Kim, Chang Wook
Nam, Soon Woo
Bae, Si Hyun
Choi, Jong Young
Yoon, Seung Kew
author_sort Lee, Jaejun
collection PubMed
description Background/Aims: Lenvatinib was recently approved as a first-line oral multikinase inhibitor for unresectable hepatocellular carcinoma (HCC). In this study, we aimed to compare the efficacy and safety of lenvatinib and sorafenib for the treatment of unresectable HCC in patients with prior failure of transarterial treatment. Methods: Between January 2019 and September 2020, 98 unresectable HCC patients treated with lenvatinib or sorafenib as salvage therapy were enrolled from five Korean university-affiliated hospitals. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate were calculated to assess the antitumor response. Results: A total of 43 and 55 patients were treated with lenvatinib and sorafenib, respectively, as salvage therapy after the failure of transarterial treatments. The median PFS was 4.97 months in the lenvatinib group and 2.47 months in the sorafenib group (p = 0.001, log-rank test). The ORR was significantly higher in the lenvatinib group (25.6%) than in the sorafenib group (3.6%, p = 0.002). Use of lenvatinib over sorafenib (hazard ratio: 0.359, 95% confidence interval: 0.203–0.635, p < 0.001) was the most significant factor for a favorable PFS after the failure of transarterial treatments in all enrolled patients. For favorable OS, achieving objective response was the significant factor (hazard ratio 0.356, 95% confidence interval: 0.132–0.957, p = 0.041). There were no significant differences in the safety profile between the two groups. Conclusions: In this real-world study, lenvatinib was demonstrated to be more efficacious than sorafenib as a salvage therapy for transarterial treatments in unresectable HCC.
format Online
Article
Text
id pubmed-7767204
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77672042020-12-28 A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC Lee, Jaejun Sung, Pil Soo Yang, Hyun Lee, Soon Kyu Nam, Hee Chul Yoo, Sun Hong Lee, Hae Lim Kim, Hee Yeon Lee, Sung Won Kwon, Jung Hyun Jang, Jeong Won Kim, Chang Wook Nam, Soon Woo Bae, Si Hyun Choi, Jong Young Yoon, Seung Kew J Clin Med Article Background/Aims: Lenvatinib was recently approved as a first-line oral multikinase inhibitor for unresectable hepatocellular carcinoma (HCC). In this study, we aimed to compare the efficacy and safety of lenvatinib and sorafenib for the treatment of unresectable HCC in patients with prior failure of transarterial treatment. Methods: Between January 2019 and September 2020, 98 unresectable HCC patients treated with lenvatinib or sorafenib as salvage therapy were enrolled from five Korean university-affiliated hospitals. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate were calculated to assess the antitumor response. Results: A total of 43 and 55 patients were treated with lenvatinib and sorafenib, respectively, as salvage therapy after the failure of transarterial treatments. The median PFS was 4.97 months in the lenvatinib group and 2.47 months in the sorafenib group (p = 0.001, log-rank test). The ORR was significantly higher in the lenvatinib group (25.6%) than in the sorafenib group (3.6%, p = 0.002). Use of lenvatinib over sorafenib (hazard ratio: 0.359, 95% confidence interval: 0.203–0.635, p < 0.001) was the most significant factor for a favorable PFS after the failure of transarterial treatments in all enrolled patients. For favorable OS, achieving objective response was the significant factor (hazard ratio 0.356, 95% confidence interval: 0.132–0.957, p = 0.041). There were no significant differences in the safety profile between the two groups. Conclusions: In this real-world study, lenvatinib was demonstrated to be more efficacious than sorafenib as a salvage therapy for transarterial treatments in unresectable HCC. MDPI 2020-12-21 /pmc/articles/PMC7767204/ /pubmed/33371271 http://dx.doi.org/10.3390/jcm9124121 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Jaejun
Sung, Pil Soo
Yang, Hyun
Lee, Soon Kyu
Nam, Hee Chul
Yoo, Sun Hong
Lee, Hae Lim
Kim, Hee Yeon
Lee, Sung Won
Kwon, Jung Hyun
Jang, Jeong Won
Kim, Chang Wook
Nam, Soon Woo
Bae, Si Hyun
Choi, Jong Young
Yoon, Seung Kew
A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
title A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
title_full A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
title_fullStr A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
title_full_unstemmed A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
title_short A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
title_sort real-world comparative analysis of lenvatinib and sorafenib as a salvage therapy for transarterial treatments in unresectable hcc
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767204/
https://www.ncbi.nlm.nih.gov/pubmed/33371271
http://dx.doi.org/10.3390/jcm9124121
work_keys_str_mv AT leejaejun arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT sungpilsoo arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT yanghyun arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT leesoonkyu arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT namheechul arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT yoosunhong arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT leehaelim arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT kimheeyeon arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT leesungwon arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT kwonjunghyun arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT jangjeongwon arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT kimchangwook arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT namsoonwoo arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT baesihyun arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT choijongyoung arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT yoonseungkew arealworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT leejaejun realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT sungpilsoo realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT yanghyun realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT leesoonkyu realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT namheechul realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT yoosunhong realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT leehaelim realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT kimheeyeon realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT leesungwon realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT kwonjunghyun realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT jangjeongwon realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT kimchangwook realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT namsoonwoo realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT baesihyun realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT choijongyoung realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc
AT yoonseungkew realworldcomparativeanalysisoflenvatinibandsorafenibasasalvagetherapyfortransarterialtreatmentsinunresectablehcc